Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Receivables: 2016-2024

Historic Receivables for RedHill Biopharma (RDHL) over the last 9 years, with Dec 2024 value amounting to $2.5 million.

  • RedHill Biopharma's Receivables rose 449.28% to $5.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $11.5 million, marking a year-over-year decrease of 14.02%. This contributed to the annual value of $2.5 million for FY2024, which is 2.01% down from last year.
  • As of FY2024, RedHill Biopharma's Receivables stood at $2.5 million, which was down 2.01% from $2.6 million recorded in FY2023.
  • In the past 5 years, RedHill Biopharma's Receivables registered a high of $34.5 million during FY2022, and its lowest value of $2.5 million during FY2024.
  • Over the past 3 years, RedHill Biopharma's median Receivables value was $2.6 million (recorded in 2023), while the average stood at $13.2 million.
  • In the last 5 years, RedHill Biopharma's Receivables skyrocketed by 2,256.50% in 2020 and then slumped by 92.49% in 2023.
  • Over the past 5 years, RedHill Biopharma's Receivables (Yearly) stood at $28.7 million in 2020, then rose by 10.55% to $31.7 million in 2021, then grew by 8.98% to $34.5 million in 2022, then tumbled by 92.49% to $2.6 million in 2023, then fell by 2.01% to $2.5 million in 2024.